Xenothera, founded in 2014, develops innovative biotherapeutics for immunosuppression, especially for use in the field of organ transplantation.
The company’s expertise focuses on transplants (rejected) and nosocomial infections. The company’s early work focused on preventing acute rejection of transplanted organs, and developed treatments with fewer harmful side effects than commonly used treatments.
Xenothera has patented this initial technology in transplant-related applications in which modified animal antibodies are used for bioproduction.